Can you stay on Wegovy for life — and what happens if you stop?

What the withdrawal trial actually showed, and why it matters

The clearest evidence on this question comes from a controlled withdrawal phase added to the STEP 1 programme. Participants who had lost an average of around 15% of their body weight on semaglutide 2.4mg were then randomised to either continue or switch to placebo. Within 68 weeks of stopping, those who stopped regained, on average, about two-thirds of the weight they had lost. The STEP 1 trial, published in the New England Journal of Medicine, is the evidence base NICE drew on when appraising Wegovy, and understanding its results is the foundation for any honest answer to whether you stay on it long-term.

What the data does not show is that weight regain is universal, inevitable or the same for everyone. A meaningful proportion of participants maintained much of their loss. The trial also ran for a fixed period; it was not designed to answer what happens across a decade of continued use. That ambiguity is precisely why the question sits with a prescriber rather than a package insert.

If you are already on treatment and wondering about the long game, the question of whether you have to stay on Wegovy long-term is worth reading alongside this page.

What the NICE recommendation actually says about duration

NICE's appraisal of semaglutide for weight management, TA875, recommends use for a maximum of two years when treatment is provided through NHS specialist weight management services. That two-year cap is part of the NHS commissioning framework, it is not a biological ceiling on how long the drug can work. Private prescribing operates under the licensed indications and individual clinical assessment rather than the NHS service model, so the picture is more nuanced in a private setting.

NICE's guidance also recommends stopping if less than 5% weight loss has been achieved after six months at the maintenance dose. That decision rule exists to avoid indefinite exposure without meaningful benefit, which is sensible medicine, not a blanket verdict on long-term use for people responding well.

For context on how Wegovy fits into the wider landscape of licensed weight-management treatments in the UK, that overview covers eligibility and how the NHS and private routes compare.

What changes at the 7.2mg dose, and does it shift the long-term calculation?

In April 2026 the MHRA approved a dedicated single-dose 7.2mg Wegovy pen, after approving the 7.2mg dose itself in January that year. Trials at this higher maintenance dose reported around 20.7% average weight loss over 72 weeks, a result that approaches what tirzepatide achieves and is meaningfully greater than the 2.4mg figure from STEP 1. The MHRA's announcement of the 7.2mg pen approval confirmed it is licensed for adults with a BMI of 30 or above, with the same titration starting point of 0.25mg.

Greater efficacy at higher doses does not settle the duration question on its own, but it does mean that the trade-off analysis (benefit of staying on versus risk of stopping) looks different now than it did when 2.4mg was the ceiling. A prescriber reviewing treatment at the two-year mark has more options than before. Whether any of those options suits you is something our clinical team discusses at every review. You can read more about the mechanism and evidence behind semaglutide if you want the background before that conversation.

Making a decision: what a prescriber weighs up

The honest framing here is that obesity is a chronic condition. Biology, not willpower, drives the appetite signals that return when the medicine stops, and that is not a controversial claim; it is the basis on which NICE and the NHS now fund these medicines at all. A prescriber thinking about long-term treatment considers how much weight has been lost, whether weight-related conditions (high blood pressure, type 2 diabetes, sleep apnoea) have improved or resolved, what lifestyle changes are in place, and what the patient actually wants.

Some people use Wegovy for a defined period to reach a stable weight and then work with a dietitian to maintain it without medication. Others continue indefinitely because the health benefits are ongoing and the side-effect profile is acceptable. Neither path is automatically right. The question of being on Wegovy long-term does not have a single clinical answer, which is a feature, not a flaw, of how good prescribing works.

It is also worth knowing that stopping Wegovy does not mean starting from scratch. If you are weighing up whether you can take Wegovy for life and what that involves in practice, that page sets out the clinical and practical considerations in detail. Exploring the full range of weight-management treatment options is a useful step if your circumstances or preferences change over time. Some patients transition to a different medicine; some focus on dietary and activity changes; some restart semaglutide after a planned break. The key is that none of those routes should happen without clinical input. Our prescribers are available seven days a week for aftercare conversations, not just at the point of starting treatment. If you'd like to talk through whether Wegovy is something you would need to take for life given your situation, speaking to our prescribers is the place to start.